I think things will liven up when they announce the trial conditions and start date. I am guessing the trial will be around 385 patients based on a 95% confidence level. If it is, i think the market will look at it very favourably, especially if we get $25k reimbursement and continued sales post final operation. Continued sales is extremely good as a 1 year wait from last operation to fda approval with nothing in between would see a decent drift in share price.
I think things will liven up when they announce the trial...
Add to My Watchlist
What is My Watchlist?
